Journal of Clinical Medicine,
Journal Year:
2025,
Volume and Issue:
14(5), P. 1446 - 1446
Published: Feb. 21, 2025
Background/Objectives:
Pulmonary
comorbidities,
such
as
chronic
obstructive
pulmonary
disease
(COPD),
asthma,
and
interstitial
lung
diseases
(ILDs),
have
emerged
critical
factors
influencing
the
severity
outcomes
of
COVID-19.
This
review
aims
to
evaluate
interplay
between
these
comorbidities
COVID-19,
both
during
acute
phase
in
long-term
recovery,
focusing
on
their
impact
clinical
management
outcomes.
Methods:
systematic
examined
studies
sourced
from
major
medical
databases,
including
PubMed
Scopus,
using
keywords
“COVID-19”,
“pulmonary
comorbidities”,
“long
COVID”,
“respiratory
sequelae”.
Peer-reviewed
articles
published
January
2020
present
were
included,
with
data
extracted
effects
COVID-19
patients.
Results:
Patients
COPD
demonstrated
significantly
higher
risks
severe
increased
hospitalization
mortality.
Asthma,
while
less
consistently
associated
outcomes,
showed
a
variable
risk
based
control.
ILDs
strongly
correlated
poor
rates
respiratory
failure
Long-term
complications,
persistent
dyspnea,
impaired
function,
structural
changes
like
fibrosis,
prevalent
patients
recovering
moderate
These
complications
adversely
affected
quality
life
healthcare
dependency.
Conclusions:
amplify
consequences
Effective
necessitates
tailored
strategies
addressing
phases,
integrating
rehabilitation
continuous
monitoring
mitigate
impairments.
Future
research
should
prioritize
understanding
mechanisms
behind
interactions
inform
public
health
interventions
improve
patient
PLoS ONE,
Journal Year:
2025,
Volume and Issue:
20(3), P. e0316553 - e0316553
Published: March 6, 2025
To
assess
how
changes
in
outpatient
services
during
the
first
year
of
COVID-19
pandemic
were
related
to
acute
healthcare
use
(emergency
department
or
hospitalizations)
for
individuals
with
asthma
chronic
obstructive
pulmonary
disease
(COPD).
We
conducted
an
observational
study
using
health
administrative
data
Ontario
(Canada)
from
January
2016
March
2021
on
all
adults
diagnosed
COPD.
used
monthly
time
series
auto-regressive
integrated
moving-average
(ARIMA)
and
pre-pandemic
rates
(January
February
2020)
calculate
projected
(i.e.,
a
had
not
occurred)
(March
2020
2021),
Quasi-Poisson
models
two-way
interaction
estimate
crude
adjusted
rate
ratios.
In
year,
COPD,
visit
started
lower
than
(Mar-May
2020),
returned
middle
(Jun-Aug
then
rose
higher
between
Sep
Mar
2021:
observed
80,293
per
100,000
persons
vs.
74,192
(95%
CI:
68,926-79,868)
asthma,
92,651
85,871
79,975-92,207)
Acute
care
remained
below
year.
While
function
test
(PFT)
both
populations,
decrease
visits
pandemic,
compared
pre-pandemic,
was
noted
months
highest
PFT
(interaction
p-values
<
0.0001).
Despite
COPD
being
ambulatory-care
sensitive
conditions,
beginning
associated
increased
use.
Lower
rates,
suggesting
that
access
is
likely
important
BMC Medicine,
Journal Year:
2025,
Volume and Issue:
23(1)
Published: April 30, 2025
The
aim
of
our
study
was
to
determine
whether
the
application
machine
learning
could
predict
PASC
by
using
diagnoses
from
primary
care
and
prescribed
medication
1
year
prior
diagnosis.
This
population-based
case-control
included
subjects
aged
18-65
years
Sweden.
Stochastic
gradient
boosting
used
develop
a
predictive
model
received
in
care,
hospitalization
due
acute
COVID-
19,
medication.
variables
with
normalized
relative
influence
(NRI)
≥
1%
showed
were
considered
predictive.
Odds
ratios
marginal
effects
(ORME)
calculated.
47,568
cases
controls.
More
females
(n
=
5113)
than
males
2815)
diagnosed
PASC.
Key
factors
identified
both
sexes
19
(NRI
16.1%,
ORME
18.8
for
females;
NRI
41.7%,
31.6
males),
malaise
fatigue
14.5%,
4.6
11.5%,
7.9
post-viral
related
syndromes
10.1%,
21.1
6.4%,
28.4
males).
Machine
can
based
on
previous
medications.
Use
this
AI
method
support
diagnostics
provide
insight
into
etiology.
Scientific Reports,
Journal Year:
2024,
Volume and Issue:
14(1)
Published: June 16, 2024
Abstract
While
studies
have
suggested
increased
risks
of
severe
COVID-19
infection
in
chronic
obstructive
pulmonary
disease
(COPD),
the
persistent
and
delayed
consequences
on
patients
with
COPD
upon
recovery
remain
unknown.
A
prospective
clinical
study
was
conducted
Hong
Kong
to
investigate
outcomes
who
had
different
severity
(mild-moderate
COVID-19),
compared
those
did
not.
Chinese
≥
40
years
old
were
recruited
from
March
September
2021.
They
prospectively
followed
up
for
24.9
±
5.0
months
until
31st
August
2023.
The
primary
outcome
deterioration
control
defined
as
change
mMRC
dyspnea
scale.
secondary
included
exacerbation
frequency
non-COVID-19
respiratory
mortality
(including
death
or
bacterial
pneumonia).
328
analysis.
Patients
mild-moderate
statistically
significant
worsening
dyspnoea
scale
by
increase
1
score
baseline
follow-up
adjusted
odds
ratios
4.44
(95%
CI
=
1.95–10.15,
p
<
0.001)
6.77
2.08–22.00,
respectively.
significantly
4.73
1.55–14.41,
0.006)
pneumonia
hazard
ratio
11.25
2.98–42.45,
0.001).
After
COVID-19,
dyspnea,
(COPD
pneumonia)
observed
among
COVID-19.
Mild
moderate
also
associated
symptomatic
deterioration.
Vaccines,
Journal Year:
2023,
Volume and Issue:
11(8), P. 1392 - 1392
Published: Aug. 21, 2023
Background/Objective:
Little
is
known
about
the
impact
of
COVID-19
pandemic
on
mortality
from
COPD
at
population
level.
The
objective
was
to
investigate
COPD-related
throughout
different
epidemic
waves
in
Italy
before
and
after
vaccination
campaign,
which
started
late
December
2020
initially
targeted
aged
≥80
years.
Methods:
Death
certificates
residents
Veneto
(Northeastern
Italy)
≥40
years
between
2008
2021
were
analyzed.
Age-standardized
morality
rates
computed
for
death
with
any
mention
COPD.
Generalized
estimating
equation
(GEE)
models
fitted
estimate
expected
during
pandemic.
results
stratified
by
age
groups
40–79
years,
main
comorbidities,
place
death.
Results:
mentioned
3478
(+14%
compared
2018–2019
average)
3133
(+3%).
increased
all
sex
2020;
2021,
returned
pre-pandemic
levels
among
elderly
but
not
(+6%).
GEE
confirmed
this
differential
trend
age.
peaks
observed,
especially
first
waves,
identified
as
underlying
cause
a
relevant
proportion
(up
35%
November
2020–January
2021).
Mortality
comorbid
diabetes
hypertensive
diseases
slightly
Conclusion:
beginning
pandemic,
due
deaths
COVID-19.
start
campaign
associated
an
important
decline
mortality,
elderly,
who
benefited
vaccines.
study
findings
show
role
mass
reducing
later
phases
Vaccines,
Journal Year:
2024,
Volume and Issue:
12(4), P. 414 - 414
Published: April 14, 2024
The
emergence
of
novel
coronavirus
mutations
and
signs
the
waning
immunity
provided
by
COVID-19
vaccines
underscore
importance
regular
vaccination.
This
study
aimed
to
investigate
prevalence
vaccination
hesitancy
factors
that
influence
it
among
patients
with
asthma
or
chronic
obstructive
pulmonary
disease
(COPD)
who
visited
primary
care
centers.
cross-sectional
was
conducted
in
six
healthcare
centers
Crete,
Greece
(October–December
2023).
Participants
completed
a
questionnaire,
which
included
questions
about
socio-demographic
characteristics,
health
status,
previous
booster
vaccination,
attitudes,
beliefs
Multivariate
logistic
regression
used
identify
influenced
vaccine
hesitancy.
Of
264
participants,
65%
exhibited
towards
Female
gender,
middle
age,
lower
educational
attainment,
depression
diagnosis,
concerns
side
effects,
lack
confidence
efficacy,
reliance
on
media
information
were
positively
associated
Conversely,
those
having
cardiovascular
type
2
diabetes,
generally
adhering
recommendations
treating
physician,
previously
received
flu
more
than
three
doses
vaccinations.
Consequently,
our
findings
could
help
develop
strategies
potentially
reduce
COPD.